ArticleMedicine2016
Renal Function and All-Cause Mortality Risk Among Cancer Patients.
Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?Radiation oncology (London, England) · 2020Trial
- Clinical characteristics and outcomes of Hodgkin Lymphoma: A single institution retrospective cohort study.PloS one · 2026Article
- Dynamic serum chloride trajectories predict short- and long-term mortality in patients with malignancies: a retrospective cohort study with external validation.Frontiers in oncology · 2026Article
- Synthetic Flozins in Cancer Prevention and Combination Strategies: Structural Insights and Therapeutic Potential.Molecules (Basel, Switzerland) · 2025Review
- Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta‑analysis.Oncology letters · 2024Article
- Article
- Role of Cisplatin in Inducing Acute Kidney Injury and Pyroptosis in Mice via the Exosome miR-122/ELAVL1 Regulatory Axis.Physiological research · 2023Article
- Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.International journal of clinical oncology · 2023Review
- Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study.The oncologist · 2023Article
- Association between rapid renal function deterioration and cancer mortality in the elderly: A retrospective cohort study.Cancer medicine · 2023Article
- Factors that Influence 2-Year Progression-Free Survival Among Head and Neck Cancer Patients.Journal of epidemiology and global health · 2022Article
- Elucidation of optimal proteinuria management based on the risk of ramucirumab-induced proteinuria.Oncology letters · 2022Article
- Prognostic Impact of Preoperative Renal Insufficiency on Metastasis-Free Survival after Radical Cystectomy.Journal of Cancer · 2021Article
- The basics of onco-nephrology in the renal clinic.Journal of nephrology · 2020Review
- Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed.European journal of clinical pharmacology · 2020Observational
- Development of a clinical diagnostic tool to differentiate multiple myeloma from bone metastasis in patients with destructive bone lesions (MM-BM DDx).BMC family practice · 2020Article
- Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease.JAMA network open · 2020Article
- Association between chronic kidney disease and mortality in stage IV cancer.International journal of clinical oncology · 2020Observational
- Management of nephrotoxicity of chemotherapy and targeted agents: 2020.American journal of cancer research · 2020Review
- The association of the decline in glomerular filtration rate with aggressive endometrial cancers.International urology and nephrology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal dysfunction predicts all-cause mortality in general population. However, the prevalence of renal insufficiency and its relationship with mortality in cancer patients are unclear.We retrospectively studied 9465 patients with newly diagnosed cancer from January 2010 to December 2010. Renal insufficiency was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m using the Chronic Kidney Disease Epidemiology Collaboration equation. The hazard ratio (HR) of all-cause mortality associated with baseline eGFR was assessed by Cox regression.Three thousand sixty-nine patients (32.4%) exhibited eGFR <90 mL/min/1.73 m and 3% had abnormal serum creatinine levels at the time of diagnosis. Over a median follow-up of 40.5 months, 2705 patients (28.6%) died. Compared with the reference group (eGFR ≥ 60 mL/min/1.73 m), an elevated all-cause mortality was observed among patients with eGFR < 60 mL/min/1.73 m stratified by cancer stage in the entire cohort, the corresponding hazard ratios were 1.87 (95% CI, 1.41-2.47) and 1.28 (95% CI, 1.01-1.62) for stage I to III and stage IV, respectively. However, this relationship was not observed after multivariate adjustment. Subgroup analysis found that eGFR < 60 mL/min/1.73 m independently predicted death among patients with hematologic (adjusted HR 2.93, 95% CI [1.36-6.31]) and gynecological cancer (adjusted HR 2.82, 95% CI [1.19-6.70]), but not in those with other cancer. Five hundred fifty-seven patients (6%) had proteinuria. When controlled for potential confounding factors, proteinuria was a risk factor for all-cause mortality among patients in the entire cohort, regardless of cancer stage and eGFR values. When patients were categorized by specific cancer type, the risk of all-cause death was only significant in patients with digestive system cancer (adjusted HR, 1.85 [1.48-2.32]).The prevalence of renal dysfunction was common in patients with newly diagnosed cancer. Patients with eGFR < 60 mL/min/1.73 m or proteinuria were associated with increased risk for all-cause mortality, this relation depended on cancer site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.